3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
3
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
40
Lymphoma, Non-Hodgkin
39
Lymphoma, Follicular
24
Lymphoma
22
Lymphoma, Large B-Cell, Diffuse
19
Lymphoma, Mantle-Cell
18
Lymphoma, B-Cell
10
Recurrence
9
Neoplasms
8
Lymphoma, B-Cell, Marginal Zone
8
Leukemia
6
Hodgkin Disease
6
Multiple Myeloma
4
Hematologic Diseases
4
Lymphoma, T-Cell, Peripheral
3
Advanced Solid Tumor
2
Waldenstrom Macroglobulinemia
1
Tumor Lysis Syndrome
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms, Plasma Cell
1
Lymphoproliferative Disorders
1
Lymphatic Diseases
1
Interventions
Rituximab
8
dacetuzumab
5
blinatumomab
5
ibrutinib
3
Cyclophosphamide
3
tetulomab tetraxetan lu-177
2
ponatinib
2
cobomarsen
2
acalabrutinib
2
Vincristine
2
Prednisone
2
Lutetium
2
Ifosfamide
2
Everolimus
2
Etoposide
2
Doxorubicin
2
Carboplatin
2
venetoclax
1
sepantronium
1
pomalidomide
1
obinutuzumab
1
fludarabine
1
ficlatuzumab
1
enzalutamide
1
durvalumab
1
denileukin diftitox
1
cirmtuzumab
1
amonafide
1
Vorinostat
1
Tinzaparin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphatic Diseases
×
Bendamustine Hydrochloride
×
Clear all
NCT02733042
2023-11-18
FUSION NHL 001
Celgene
Phase 1/2
Completed
106 enrolled
48 charts